Henry H. Hsu

Bellevue College — United States

Medicine · Health Sciences

24h-index4.8kcitations102works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(20), Acute Myeloid Leukemia Research(16), Musculoskeletal synovial abnormalities and treatments(15), Lung Cancer Treatments and Mutations(13), Neuroendocrine Tumor Research Advances(12)

Publications102 total

Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy
Molecular Metabolism·2025Open Access
Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy
2024Open Access
Development of a non-invasive bioassay for adiponectin target engagement in mice
iScience·2024· 1 citedOpen Access
The adiponectin‐derived peptide <scp>ALY688</scp> protects against the development of metabolic dysfunction‐associated steatohepatitis
Clinical and Translational Science·2024· 6 citedOpen Access
A novel blood-based bioassay to monitor adiponectin signaling
International Immunopharmacology·2024· 6 citedOpen Access
Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF)
Biomedicine & Pharmacotherapy·2024· 12 citedOpen Access
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Neuro-Oncology Advances·2024· 6 citedOpen Access
The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.<i>mdx</i> mouse model of Duchenne muscular dystrophy
American Journal of Physiology-Cell Physiology·2023· 16 cited
Abstract P2118: Intervention With The Adiponectin Mimetic Peptide ALY688 Protects Against Cardiac Dysfunction Induced By Ischemia Reperfusion Injury
Circulation Research·2023
Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage
Hematological Oncology·2023· 1 citedOpen Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
2023Open Access
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
2023Open Access
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
2023Open Access
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
2023Open Access
Supplementary Data from Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
2023Open Access
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
2023Open Access
page 1 of 6Next →

Frequent Co-authors

William D. Tap(11), Andrew J. Wagner(10), John H. Healey(9), Paul Lin(9), Brian L. West(8), Charles Peterfy(8), Zev A. Wainberg(7), Harry B. Greenberg(6), Stephen P. Anthony(5), Bartosz Chmielowski(5), Geoffrey I. Shapiro(5), Vicki L. Keedy(5), Arun S. Singh(5), Heather L. Gelhorn(5), Sandra Tong(5), Allen Lee Cohn(4), Igor Puzanov(4), Sandra Tong-Starksen(4), Gideon Bollag(4), Howard Colman(4)